AGI-5198, a selective inhibitor of mutant IDH1 (R132H), has been shown to suppress tumor growth and induce differentiation in IDH1-mutant cancer cells, including colorectal cancer models, suggesting its promise in targeted therapy for specific molecular subtypes (63, 64). Here, IDH1 is linked to neoplasm.